Current and historical daily PE Ratio for DCPH (
Deciphera Pharmaceuticals Inc
) from 2017 to Sep 27 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Deciphera Pharmaceuticals stock (DCPH) PE ratio as of Sep 27 2023 is 0.
More Details
Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Chart
Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1258
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Deciphera Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-09-28 | At Loss | 2023-07-25 | At Loss |
| 2023-09-26 | At Loss | 2023-07-24 | At Loss |
| 2023-09-25 | At Loss | 2023-07-21 | At Loss |
| 2023-09-22 | At Loss | 2023-07-20 | At Loss |
| 2023-09-21 | At Loss | 2023-07-19 | At Loss |
| 2023-09-20 | At Loss | 2023-07-18 | At Loss |
| 2023-09-19 | At Loss | 2023-07-17 | At Loss |
| 2023-09-18 | At Loss | 2023-07-14 | At Loss |
| 2023-09-15 | At Loss | 2023-07-13 | At Loss |
| 2023-09-14 | At Loss | 2023-07-12 | At Loss |
| 2023-09-13 | At Loss | 2023-07-11 | At Loss |
| 2023-09-12 | At Loss | 2023-07-10 | At Loss |
| 2023-09-11 | At Loss | 2023-07-07 | At Loss |
| 2023-09-08 | At Loss | 2023-07-06 | At Loss |
| 2023-09-07 | At Loss | 2023-07-05 | At Loss |
| 2023-09-06 | At Loss | 2023-07-03 | At Loss |
| 2023-09-05 | At Loss | 2023-06-30 | At Loss |
| 2023-09-01 | At Loss | 2023-06-29 | At Loss |
| 2023-08-31 | At Loss | 2023-06-28 | At Loss |
| 2023-08-30 | At Loss | 2023-06-27 | At Loss |
| 2023-08-29 | At Loss | 2023-06-26 | At Loss |
| 2023-08-28 | At Loss | 2023-06-23 | At Loss |
| 2023-08-25 | At Loss | 2023-06-22 | At Loss |
| 2023-08-24 | At Loss | 2023-06-21 | At Loss |
| 2023-08-23 | At Loss | 2023-06-20 | At Loss |
| 2023-08-22 | At Loss | 2023-06-16 | At Loss |
| 2023-08-21 | At Loss | 2023-06-15 | At Loss |
| 2023-08-18 | At Loss | 2023-06-14 | At Loss |
| 2023-08-17 | At Loss | 2023-06-13 | At Loss |
| 2023-08-16 | At Loss | 2023-06-12 | At Loss |
| 2023-08-15 | At Loss | 2023-06-09 | At Loss |
| 2023-08-14 | At Loss | 2023-06-08 | At Loss |
| 2023-08-11 | At Loss | 2023-06-07 | At Loss |
| 2023-08-10 | At Loss | 2023-06-06 | At Loss |
| 2023-08-09 | At Loss | 2023-06-05 | At Loss |
| 2023-08-08 | At Loss | 2023-06-02 | At Loss |
| 2023-08-07 | At Loss | 2023-06-01 | At Loss |
| 2023-08-04 | At Loss | 2023-05-31 | At Loss |
| 2023-08-03 | At Loss | 2023-05-30 | At Loss |
| 2023-08-02 | At Loss | 2023-05-26 | At Loss |
| 2023-08-01 | At Loss | 2023-05-25 | At Loss |
| 2023-07-31 | At Loss | 2023-05-24 | At Loss |
| 2023-07-28 | At Loss | 2023-05-23 | At Loss |
| 2023-07-27 | At Loss | 2023-05-22 | At Loss |
| 2023-07-26 | At Loss | 2023-05-19 | At Loss |
Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Deciphera Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US24344T1016
Compare
Compare
Traded in other countries / regions
DCPH.USAD05.Germany IPO Date
2017-09-28Description
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers